The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Overcoming T-cell exhaustion with iPSC technology in the treatment of myeloma
In this video, Jooeun Bae, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly highlights the challenges associated with CAR-T therapy, drawing focus on T-cell exhaustion and the limitations this puts on CAR-T. Dr Bae then explains how the use of induced pluripotent stem cell (iPSC) technology allows for T-cells to be rejuvenated while overcoming the challenge of T-cell exhaustion, and the benefits that this technology can bring to the treatment of patients with myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
